Avadel Pharmaceuticals Plc - Company Profile
Powered by 
All the data and insights you need on Avadel Pharmaceuticals Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Avadel Pharmaceuticals Plc Strategy Report
- Understand Avadel Pharmaceuticals Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (narcolepsy), pain, respiratory diseases and diabetes. It’s products are built on its proprietary polymer-based technologies: Micropump, an oral sustained release microparticles platform, LiquiTime, a Micropump – derived platform for liquid oral products, and Medusa that enables controlled release of injectables. It sells products in the US and Ireland. The company operates in St. Louis, Missouri and Charlotte in the US. Avadel is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
Block 10-1 Blanchardstown Corporate Park, Ballycoolin, Dublin, 15
Website
www.avadel.com
Telephone
353 1 9015201
No of Employees
154
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AVDL (NASD)
Revenue (2022)
$28.0M
EPS
XYZ
Net Income (2022)
XYZ
-16.6%
(2022 vs 2021)
Market Cap*
$1.6B
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Avadel Pharmaceuticals Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline Product: |
| FT218 (excessive daytime sleepiness and cataplexy in adults with narcolepsy) |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In May, the company announced the approval and grant of orphan drug status for LUMRYZ. |
| 2023 | Contracts/Agreements | In March, the company entered into an agreement with RTW Investments to acquire royalty for US$75 million. |
| 2022 | Others | In November, the company announced favorable ruling on its motion to delist REMS patent from FDA’s Orange Book. |
Competitor Comparison
| Key Parameters | Avadel Pharmaceuticals Plc | Elite Pharmaceuticals Inc | DURECT Corp | Acura Pharmaceuticals Inc | Albireo Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | Ireland | United States of America | United States of America | United States of America | United States of America |
| City | Dublin | Northvale | Cupertino | Palatine | Boston |
| State/Province | - | New Jersey | California | Illinois | Massachusetts |
| No. of Employees | 154 | 53 | 58 | 14 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Geoffrey M. Glass | Chairman | Executive Board | 2018 | 49 |
| Gregory J. Divis | Chief Executive Officer; Director | Executive Board | 2019 | 56 |
| Thomas S. McHugh | Chief Financial Officer | Senior Management | 2019 | 58 |
| Richard Kim | Chief Commercial Officer | Senior Management | 2021 | 53 |
| AngieWoods | Vice President - People and Culture | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward